FENC logo

Fennec Pharmaceuticals (FENC) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

15 September 2017

Indexes:

Not included

Description:

Fennec Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare diseases. They specialize in innovative therapies, particularly for pediatric patients. Their main product, Pedmark, is designed to reduce hearing loss caused by chemotherapy in children. Fennec aims to improve the quality of life for patients.

Key Details

Price

$6.01

Annual Revenue

$21.25 M(+1284.50% YoY)

Annual EPS

-$0.60(+33.33% YoY)

Annual ROE

138.06%

Beta

0.86

Events Calendar

Earnings

Next earnings date:

Mar 21, 2025

Recent quarterly earnings:

Nov 07, 2024

Recent annual earnings:

Mar 21, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Sept 09, 2014

Analyst ratings

Recent major analysts updates

22 Aug '24 HC Wainwright & Co.
Buy
14 Aug '24 Craig-Hallum
Buy
15 May '24 HC Wainwright & Co.
Buy
15 May '24 Craig-Hallum
Buy
04 Apr '24 HC Wainwright & Co.
Buy
18 Mar '24 Craig-Hallum
Buy
04 Aug '23 HC Wainwright & Co.
Buy
21 June '23 HC Wainwright & Co.
Buy
06 Apr '23 Cantor Fitzgerald
Overweight
04 Apr '23 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Fennec Pharmaceuticals Inc. (FENC) Q3 2024 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (FENC) Q3 2024 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (FENC) Q3 2024 Earnings Call Transcript
FENC
seekingalpha.com09 November 2024

Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q3 2024 Earnings Conference Call November 9, 2024 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Jeff Hackman - Chief Executive Officer and Director Conference Call Participants Chase Knickerbocker - Craig-Hallum Raghuram Selvaraju - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Third Quarter 2024 Earnings and Corporate Update Conference Call.

Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
FENC
globenewswire.com07 November 2024

~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARK ~ ~ Strengthened Executive Leadership Team with Chief Medical Officer, Chief Commercial Officer & Chief Strategy Officer Appointments ~ ~ Company Has Approximately $40 Million in Cash, Cash Equivalents, and Investment Securities Expected to Fund Operations Into at Least 2026 ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C.

Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
FENC
globenewswire.com31 October 2024

RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7, 2024. Management will host a conference call and webcast that day to discuss the Company's financial and business results.

Analysts Estimate Adherex Technologies Inc. (FENC) to Report a Decline in Earnings: What to Look Out for
Analysts Estimate Adherex Technologies Inc. (FENC) to Report a Decline in Earnings: What to Look Out for
Analysts Estimate Adherex Technologies Inc. (FENC) to Report a Decline in Earnings: What to Look Out for
FENC
zacks.com28 October 2024

Adherex Technologies (FENC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fennec Pharmaceuticals Inc. (FENC) Q2 2024 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (FENC) Q2 2024 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (FENC) Q2 2024 Earnings Call Transcript
FENC
seekingalpha.com13 August 2024

Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Robert Andrade - CFO Jeffrey Hackman - CEO and Board Member Conference Call Participants Chase Knickerbocker - Craig Hallum Naureen Quibria - Capital One Securities Raghuram Selvaraju - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Second Quarter 2024 Earnings and Corporate Update Conference Call.

Adherex Technologies Inc. (FENC) Reports Q2 Loss, Lags Revenue Estimates
Adherex Technologies Inc. (FENC) Reports Q2 Loss, Lags Revenue Estimates
Adherex Technologies Inc. (FENC) Reports Q2 Loss, Lags Revenue Estimates
FENC
zacks.com13 August 2024

Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.21 per share a year ago.

Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
FENC
globenewswire.com13 August 2024

~ Achieved Second Quarter 2024 Total Net Revenues of $7.3 Million ~ ~ Appointed Jeffrey S. Hackman as Chief Executive Officer (CEO) and Member of the Board of Directors ~ ~ Company Has Approximately $43 Million in Cash, Cash Equivalents, and Investment Securities ~ ~ Management to Host Conference Call Today at 8:30 a.m.

Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024
Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024
Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024
FENC
globenewswire.com06 August 2024

Company to Also Participate in 2024 Wedbush PacGrow Healthcare Conference Company to Also Participate in 2024 Wedbush PacGrow Healthcare Conference

Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director
Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director
Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director
FENC
globenewswire.com05 August 2024

~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~ ~ Assumes Leadership Role at Critical Time to Expand Use of PEDMARK®, the First and Only Approved Treatment to Reduce the Risk of Cisplatin-Induced Ototoxicity ~ RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced the appointment of Mr.

Fennec Pharmaceuticals Announces Management Change
Fennec Pharmaceuticals Announces Management Change
Fennec Pharmaceuticals Announces Management Change
FENC
globenewswire.com01 July 2024

RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that Adrian Haigh has departed from his position as Fennec's Chief Operating Officer as of June 30, 2024. After nine years as an independent director, in August 2023, Adrian joined the Fennec leadership team as Chief Operating Officer.

FAQ

  • What is the primary business of Fennec Pharmaceuticals?
  • What is the ticker symbol for Fennec Pharmaceuticals?
  • Does Fennec Pharmaceuticals pay dividends?
  • What sector is Fennec Pharmaceuticals in?
  • What industry is Fennec Pharmaceuticals in?
  • What country is Fennec Pharmaceuticals based in?
  • When did Fennec Pharmaceuticals go public?
  • Is Fennec Pharmaceuticals in the S&P 500?
  • Is Fennec Pharmaceuticals in the NASDAQ 100?
  • Is Fennec Pharmaceuticals in the Dow Jones?
  • When was Fennec Pharmaceuticals's last earnings report?
  • When does Fennec Pharmaceuticals report earnings?
  • Should I buy Fennec Pharmaceuticals stock now?

What is the primary business of Fennec Pharmaceuticals?

Fennec Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare diseases. They specialize in innovative therapies, particularly for pediatric patients. Their main product, Pedmark, is designed to reduce hearing loss caused by chemotherapy in children. Fennec aims to improve the quality of life for patients.

What is the ticker symbol for Fennec Pharmaceuticals?

The ticker symbol for Fennec Pharmaceuticals is NASDAQ:FENC

Does Fennec Pharmaceuticals pay dividends?

No, Fennec Pharmaceuticals does not pay dividends

What sector is Fennec Pharmaceuticals in?

Fennec Pharmaceuticals is in the Healthcare sector

What industry is Fennec Pharmaceuticals in?

Fennec Pharmaceuticals is in the Biotechnology industry

What country is Fennec Pharmaceuticals based in?

Fennec Pharmaceuticals is headquartered in United States

When did Fennec Pharmaceuticals go public?

Fennec Pharmaceuticals's initial public offering (IPO) was on 15 September 2017

Is Fennec Pharmaceuticals in the S&P 500?

No, Fennec Pharmaceuticals is not included in the S&P 500 index

Is Fennec Pharmaceuticals in the NASDAQ 100?

No, Fennec Pharmaceuticals is not included in the NASDAQ 100 index

Is Fennec Pharmaceuticals in the Dow Jones?

No, Fennec Pharmaceuticals is not included in the Dow Jones index

When was Fennec Pharmaceuticals's last earnings report?

Fennec Pharmaceuticals's most recent earnings report was on 7 November 2024

When does Fennec Pharmaceuticals report earnings?

The next expected earnings date for Fennec Pharmaceuticals is 21 March 2025

Should I buy Fennec Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions